Abstract
Pompe disease (PD) is due to lisosomal enzyme acid Maltase or acid alpha-glucosidase deficit and clinically lies expressed such as a myopathy. The amount and quality of enzyme establish the variety of presentation. In the following report We show the way of debut, clinical characteristics, lab findings and the follow up of two cases evaluated with PD and We made a review of the literature.
References
VAN DER PLOEG AT, REUSER AJ. Pompe's disease. Lancet 2008; 372: 1342-53.
VAN DEN HOUT HM, HOP W, VAN DIGGELEN OP, ET AL. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332-40
POMPE JC. Over idiopatische hypertrophie van het hart. Ned Tijdschr Geneeskd 1932; 76: 304.
HERS HG. Alpha-glucosidase deficiency in generalized glycogen-storage disease. (Pompes disease). Biochem J 1963; 86: 11.
CHEN YT, AMALFITANO A. Towards a molecular therapy for glycogen storage disease type II (Pompe disease). Mol Med Today 2000; 6:245-51.
HIRSCHHORN R, REUSER AJJ. Glycogen storage disease type II: acid a-glucosidase (acid maltase) deficiency. In: Scriver CK, Beaudet AL, Sly WS, et al., eds. The metabolic & molecular bases of inherited disease. 8th ed. Vol. 3. New York: McGraw-Hill, 2001:3389-420.
REUSER AJJ, KROOS MA, HERMANS MMP, ET AL. Glycogenosis type II (acid maltase deficiency). Muscle Nerve 1995; 3:S61-S69.
AUSEMS MGEM, TEN BERG K, KROOS MA, ET AL. Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency. Community Genet 1999; 2:91-96.
AUSEMS MGEM, VERBIEST J, HERMANS MMP, ET AL. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counseling. Eur J Human Genet 1999; 7:713716.
CHIEN YH, CHIANG SC, ZHANG XK, KEUTZER J, LEE NC, HUANG AC, ET AL. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics 2008; 122(1): e39-45.
ENGEL AG, GOMEZ MR, SEYBOLD ME, LAMBERT EH. The spectrum and diagnosis of acid malt-ase deficiency. Neurology 1973; 23: 95.
SLONIM AE, BULONE L, RITZ S, ET AL. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr 2000; 137:283-285.
REUSER AJJ, KROOS M, WILLEMSEN R, ET AL. Clinical diversity in glycogenosis type II: biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts. J Clin Invest 1987; 79:1689-1699.
MELLIES U, LOFASO F. Pompe disease: a neu-romuscular disease with respiratory muscle involvement. Respir Med 2009; 103(4): 477-84.
ULRICH K, VON BASSEWITZ D, SHIN J, KORINTHENBERG R, SEWELL S, VON FIGURA K. Lysosomal glycogen storage disease without deficiency of alpha-glucosidase. Prog Clin Biol Res 1989; 306: 163.
LOTZ BP. Metabolic myopathies. In: Brown WF, et al, eds. Neuromuscular Function and Disease: Basic, Clinical, and Electrodiagnostic Aspects. Vol. 2. Philadelphia: WB. Saunders Company; 2002:14431445.
LENDERS MB, MARTIN JJ, DE BARSY T, CEYTERICK C, MARCHAU M. Acid maltase deficiency in adults. Acta Neurol Belg 1986; 86: 152.
ENGEL AG. Acid maltase deficiency in adults: studies in four cases of a syndrome which may mimic muscular dystrophy or other myopathies. Brain 1970; 93: 599-616.
MELLIES U, RAGETTE R, SCHWAKE C, ET AL. Sleep-disordered breathing and respiratory failure in acid maltase deficiency. Neurology 2001; 57: 12901295.
HAGEMANS ML, WINKEL LP, VAN DOORN PA, ET AL. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005; 128: 671-7.
LAFORET P, NICOLINO M, EYMARD PB, ET AL. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 2000; 55: 1122-8.
LYNCH CM, JOHNSON J, VACCARO C, ET AL. High-resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology. JHistochem Cyto-chem 2005; 53: 63-73.
CHAMOLES NA, NIIZAWA G, BLANCO M, ET AL. Glycogen storage disease type II: enzymatic screening in dried blood spots on ilter paper. Clin Chim Acta 2004; 347: 97-102.
ROZAKLIS T, RAMSAY SL, WHITFIELD PD, ET AL. Determination of oligosaccharides in Pompe disease by electrospray ionization tandem mass spectrometry. Clin Chem 2002; 48: 131-139.
KISHNANI PS, CORZO D, LESLIE ND, ET AL. Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease. Pediatr Res 2009; 66: 329-55.
NICOLINO M, BYRNE B, WRAITH JE, ET AL. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 2009; 11: 210-9.
WINKEL LP, VAN DEN HOUT JM, KAMPHOVEN JH, ET AL. Enzyme replacement therapy in late-onset Pompe's disease: a threeyear follow-up. Ann Neurol 2004; 55: 495-502.
MELLIES U, STEHLING F, DOHNA-SCHWAKE C, RAGETTE R, TESCHLER H, VOIT T. Respiratory failure in Pompe disease: treatment with noninvasive ventilation. NEUROLOGY 2005; 64: 1465-7.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.